Needham & Company LLC reiterated their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has a $21.00 price target on the medical research company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com […]
NeoGenomics (NASDAQ:NEO) Shares Gap Down to $20 50 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $20.50, but opened at $18.05. NeoGenomics shares last traded at $17.43, with a volume of 713,161 shares traded. Wall Street Analyst Weigh In A number of research analysts have recently weighed in […]
NeoGenomics (NASDAQ:NEO) Shares Gap Down to $20 50 wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics (NASDAQ:NEO – Get Free Report) and Applied DNA Sciences (NASDAQ:APDN – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations. Earnings & Valuation This table compares NeoGenomics and […]